enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $15.01, for a total transaction of $68,670.75. Following the transaction, the insider now owns 3,084,107 shares in the company, valued at approximately $46,292,446.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
De Solidarite Des Travai Fonds also recently made the following trade(s):
- On Monday, April 22nd, De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock. The stock was sold at an average price of $15.00, for a total value of $717,810.00.
enGene Stock Performance
NASDAQ ENGN opened at $14.80 on Tuesday. enGene Holdings Inc. has a 1 year low of $6.69 and a 1 year high of $43.00. The business’s 50-day moving average is $16.11.
Analyst Ratings Changes
Read Our Latest Report on enGene
Institutional Investors Weigh In On enGene
Large investors have recently made changes to their positions in the company. Vivo Capital LLC acquired a new position in enGene in the 4th quarter worth approximately $6,264,000. Omega Fund Management LLC purchased a new stake in shares of enGene in the fourth quarter valued at $10,441,000. BVF Inc. IL acquired a new stake in shares of enGene in the fourth quarter worth $20,777,000. Finally, Fcpm Iii Services B.V. purchased a new position in shares of enGene during the fourth quarter valued at $80,097,000. Institutional investors and hedge funds own 64.16% of the company’s stock.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
- Five stocks we like better than enGene
- Using the MarketBeat Dividend Tax Calculator
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Merger or Not, Albertson’s Companies is a Good Buy
- Best Stocks Under $10.00
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.